KalVista Pharmaceuticals Announces Positive Phase 1 Data for Sebetralstat Orally Disintegrating Tablets for Use in Hereditary Angioedema | Tech Reddy
[ad_1] Cambridge, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of oral, small molecule protease inhibitors, today announced positive Phase 1 data for an orally disintegrating tablet (ODT). Its lead compound is the formula for sebetralstat. Sebetralstat is currently being developed as a … Read more